The Cisplatin Total Dose and Concomitant Radiation in Locoregionally Advanced Head and Neck Cancer: Any Recent Evidence for Dose Efficacy?
- 287 Downloads
Concurrent chemoradiotherapy (CRT) with high-dose (100 mg/m2), single-agent cisplatin is considered the standard of care for locoregionally advanced head and neck cancer (LAHNC). Poor compliance often due to significant treatment-related toxicities observed during CRT regimen has stimulated research efforts to examine for evidence of the optimal cumulative cisplatin dose and schedule. The findings from this systematic literature review demonstrate that there are insufficient prospective, randomized controlled data to determine the optimal total dose (and schedule) of cisplatin to administer concomitantly with radiotherapy in the treatment of LAHNC. Given the clinical challenges associated with administering concurrent CRT with single-agent high-dose cisplatin, as well as the long-term toxicities accompanying this treatment, an examination of the available literature for evidence of dose efficacy is of continued clinical interest. Moving forward, it is critical that researchers include complete descriptions of key disease and treatment variables (i.e. treatment compliance and HPV status) to inform and strengthen clinical decisions. The substantial heterogeneity of LAHNC has led to the focus of recent research efforts to risk-stratify using a combination of clinical and molecular markers (e.g. HPV status). Thus, the optimal total dose (and schedule) of cisplatin may need to be modified to reflect the specific characteristics of the individual patient subpopulations being treated. At present, CRT remains the standard of care for LAHNC, but this field is rapidly evolving. National and international clinical trials are ongoing to evaluate treatment de-intensification in favourable risk patient subsets and treatment intensification in poor-risk patient subsets, these will provide evidence-based guidance to individualize therapy with the ultimate goal of improving patient outcomes.
KeywordsCisplatin Chemoradiotherapy Locoregionally advanced head and neck cancer
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Gupta T, Kannan S, Ghosh-Laskar S, Agarwal JP. Concomitant chemoradiotherapy versus altered fractionation radiotherapy in the radiotherapeutic management of locoregionally advanced head and neck squamous cell carcinoma: an adjusted indirect comparison meta-analysis. Head Neck. 2015;37(5):670–6.CrossRefPubMedGoogle Scholar
- 7.• Strojan P, Vermorken JB, Beitler JJ, et al. Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: a systematic review. Head Neck. 2016;38(Suppl 1):E2151–8. A systematic review of the literature published between 1978 and 2014 evaluating optimal dose and timing of cisplatin in both definitive chemoradiotherapy (CRT) and postoperative CRT for patients with locoregionally advanced squamous cell carcinoma of the head and neck. These authors highlight several of the limitations presented in the current paperGoogle Scholar
- 14.Kunieda F, Kiyota N, Tahara M, et al. Randomized phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck: Japan Clinical Oncology Group Study (JCOG1008). Jpn J Clin Oncol. 2014;44(8):770–4.CrossRefPubMedGoogle Scholar
- 15.•• Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(27):2940–50. A phase III randomized trial RTOG0522 comparing CRT (with single-agent, cisplatin 100mg/m2) with and without cetuximab in LAHNC. This trial randomized 891 patients, captured HPV status for the oropharyngeal subset and included data on survival, disease-related and toxicity outcomesGoogle Scholar
- 19.•• Nguyen-Tan PF, Zhang Q, Ang KK, et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(34):3858–67. A phase III randomized trial RTOG0129 comparing the administration of accelerated versus conventional radiotherapy regimens administered concurrently with high-dose cisplatin (100mg/m2). Detailed treatment compliance data are provided. Multiple outcomes evaluated included OS, PFS, LRF and DM, as well as toxicity dataGoogle Scholar
- 20.Rodriguez CP, Adelstein DJ, Rybicki LA, et al. Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design. Head Neck. 2015;37(11):1583–9.CrossRefPubMedGoogle Scholar
- 21.• Driessen CM, Janssens GO, van der Graaf WT, et al. Toxicity and efficacy of accelerated radiotherapy with concurrent weekly cisplatin for locally advanced head and neck carcinoma. Head Neck. 2016;38(Suppl 1):E559–65. A retrospective review of 106 patients with LAHNC receiving CRT with weekly cisplatin (40mg/m2). This study reported acute toxicity data, as well as survival and disease-related outcomes, in addition to performing a sub-analysis of the oropharyngeal cohort based upon HPV statusGoogle Scholar
- 26.Shapiro LQ, Sherman EJ, Riaz N, et al. Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC). Oral Oncol. 2014;50(10):947–55.CrossRefPubMedPubMedCentralGoogle Scholar
- 32.O’Sullivan B, Huang SH, Siu LL, et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(5):543–50.CrossRefGoogle Scholar
- 35.• Spreafico A, Huang SH, Xu W, et al. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. Eur J Cancer. 2016;67:174–82. A retrospective analysis examining the impact of cisplatin dose intensity when administered concurrently with radiotherapy in the treatment of HPV-positive and HPV-negative LAHNC patients. Results suggest cumulative cisplatin dose of >200mg/m2 is associated with survival benefit in HPV-negative LAHNC patients but not in HPV-positive patients with the exception of T4 or N3 subset where higher cumulative cisplatin dose was associated with a trend in improved OSGoogle Scholar